MedTrace Logo

Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat

NCT02935894 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-06-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation. Additionally, the investigators want to know whether the amount and small molecule content of the sweat is the same in an individual over time, and the same across individuals at a given time. Finally, the investigators want to know how consumption of over-the-counter anti-inflammatory drugs such as ibuprofen will affect the inflammatory mediator content of sweat and how that compares to blood. This information will help to better understand the composition and behavior of sweat and assess its potential utility as a routine clinical tool in skin research.

Conditions

  • Stability & Variability of Lipid-derived Molecules in Sweat

Interventions

DRUG

Ibuprofen

400 mg ibuprofen given to inhibit cyclooxygenase metabolism

OTHER

Physiological induction of sweating

15 minutes exercise at 60-80% oxygen consumption to induce sweating

DRUG

Pilocarpine

Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating

Sponsors & Collaborators

  • University of California, Davis

    collaborator OTHER

  • USDA, Western Human Nutrition Research Center

    lead FED

Principal Investigators

  • John W. Newman, Ph.D. · USDA-ARS-Western Human Nutrition Research Center

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-28
Primary Completion
2017-06-08
Completion
2017-06-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02935894 on ClinicalTrials.gov